Stock A359090 C&R RESEARCH INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials C&R Research Inc.

Equities

A359090

KR7359090008

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
1,745 KRW +1.04% Intraday chart for C&R Research Inc. +4.80% +46.64%
2023 C&R Research Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
2021 C&R Research Co., Ltd. completed the acquisition of NH Special Purpose Acquisition 17 Company in a reverse merger transaction. CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 108,379 61,891 65,274
Enterprise Value (EV) 1 103,119 58,988 59,866
P/E ratio -3.1 x 15.6 x 12 x
Yield - - -
Capitalization / Revenue 2.51 x 1.28 x 1.18 x
EV / Revenue 2.39 x 1.22 x 1.09 x
EV / EBITDA 16 x 11 x 8.12 x
EV / FCF - 651,906,714 x 63,981,917 x
FCF Yield - 0% 0%
Price to Book 3.56 x 1.72 x 1.55 x
Nbr of stocks (in thousands) 52,484 54,291 54,852
Reference price 2 2,065 1,140 1,190
Announcement Date 3/22/22 3/22/23 3/19/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023
Net sales 1 43,171 48,498 55,102
EBITDA 1 6,435 5,358 7,377
EBIT 1 5,751 4,708 6,233
Operating Margin 13.32% 9.71% 11.31%
Earnings before Tax (EBT) 1 -2,724 4,091 5,791
Net income 1 -3,301 3,929 5,563
Net margin -7.65% 8.1% 10.09%
EPS 2 -666.0 73.00 98.80
Free Cash Flow - 90.49 935.7
FCF margin - 0.19% 1.7%
FCF Conversion (EBITDA) - 1.69% 12.68%
FCF Conversion (Net income) - 2.3% 16.82%
Dividend per Share - - -
Announcement Date 3/22/22 3/22/23 3/19/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023
Net Debt 1 - - -
Net Cash position 1 5,260 2,903 5,408
Leverage (Debt/EBITDA) - - -
Free Cash Flow - 90.5 936
ROE (net income / shareholders' equity) - 11.8% 14.1%
ROA (Net income/ Total Assets) - 4.15% 5.25%
Assets 1 - 94,647 105,927
Book Value Per Share 2 581.0 664.0 770.0
Cash Flow per Share 2 371.0 120.0 132.0
Capex 1 1,247 872 193
Capex / Sales 2.89% 1.8% 0.35%
Announcement Date 3/22/22 3/22/23 3/19/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
C&R RESEARCH INC. Stock C&R Research Inc.
+46.64% 71.14M
MODERNA, INC. Stock Moderna, Inc.
+51.13% 54.63B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-4.95% 39.92B
LONZA GROUP AG Stock Lonza Group AG
+37.60% 38.82B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+15.49% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.61% 18.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.32% 12.21B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+1.97% 12.16B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.93% 11.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. A359090 Stock
  4. Financials C&R Research Inc.